ÖZET
Toksik epidermal nekroliz (TEN) yüksek mortalite ile seyreden ciddi bir kutanöz advers reaksiyondur. Şiddetli akut solunum sendromu-koronavirüs-2 virüsü tüm dünyayı etkisi altına alan bir pandemiye koronavirüs hastalığı-2019 (COVID-19) neden olmuş ve günümüze kadar kesin bir tedavi ortaya konamamıştır. COVID-19 tedavisinde immünosüpresif ilaçların kullanılması bir tartışma konusu olmakla beraber nadir olgularda kullanımı kaçınılmazdır. Burada, TEN ve COVID-19’un eş zamanlı tedavi edilerek iyi sonuç alınan bir hastanın mevcut literatürler eşliğinde sunulması amaçlanmıştır.
References
1
See S, Mumford JM. Trimethoprim/sulfamethoxazole-induced toxic epidermal necrolysis. Ann Pharmacother 2001;35:694-7.
2
Lissia M, Mulas P, Bulla A, Rubino C. Toxic epidermal necrolysis (Lyell’s disease). Burns 2010;36:152-63.
3
Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53.
4
Jimenez-Cauhe J, Ortega-Quijano D, de Perosanz-Lobo D, Burgos-Blasco P, Vañó-Galván S, Fernandez-Guarino M, et al. Enanthem in Patients With COVID-19 and Skin Rash. JAMA Dermatol 2020;156:1134-6.
5
Rossi CM, Beretta FN, Traverso G, Mancarella S, Zenoni D. A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime? Clin Mol Allergy 2020;18:19.
6
Emadi SN, Hamzelou S, Saffarian Z, Shakoei S. Challenges in the treatment of a patient with toxic epidermal necrolysis associated with COVID-19: A case report. Dermatol Ther 2021;34:e14656.
7
Lagziel T, Quiroga L, Ramos M, Hultman CS, Asif M. Two False Negative Test Results in a Symptomatic Patient with a Confirmed Case of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Suspected Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). Cureus 2020;12:e8198.
8
Saha M, D’Cruz A, Paul N, Healy R, Collins D, Charles DA, et al. Toxic epidermal necrolysis and co-existent SARS-CoV-2 (COVID-19) treated with intravenous immunoglobulin: ‘Killing 2 birds with one stone’. J Eur Acad Dermatol Venereol 2021;35:e97-8.
9
Prete M, Favoino E, Catacchio G, Racanelli V, Perosa F. SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial? Autoimmun Rev 2020;19:102559.
10
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect 2020;80:607-13.
11
Tzilas V, Manali E, Papiris S, Bouros D. Intravenous Immunoglobulin for the Treatment of COVID-19: A Promising Tool. Respiration 2020;99:1087-9.
12
Seirafianpour F, Sodagar S, Pour Mohammad A, Panahi P, Mozafarpoor S, Almasi S, et al. Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review. Dermatol Ther 2020;33:e13986.
